FamiCord AG (ETR:V3V)
Germany
· Delayed Price · Currency is EUR | Market Cap | 77.05M |
| Revenue (ttm) | 88.29M |
| Net Income (ttm) | -9.80M |
| Shares Out | 17.43M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | 63.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,054 |
| Average Volume | 1,530 |
| Open | 4.420 |
| Previous Close | 4.420 |
| Day's Range | 4.420 - 4.500 |
| 52-Week Range | 3.800 - 7.650 |
| Beta | 0.70 |
| RSI | 20.96 |
| Earnings Date | Apr 30, 2026 |
About FamiCord AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the compa... [Read more]
Financial Performance
In 2024, FamiCord AG's revenue was 82.18 million, an increase of 6.65% compared to the previous year's 77.06 million. Losses were -12.14 million, 550.7% more than in 2023.
Financial StatementsNews
Vita 34 & FamiCord AG: 2025 Preliminary Results & 2026 Outlook
FamiCord reports solid 2025 results and cautious 2026 guidance, balancing efficiency gains with softer demand and rising geopolitical and macroeconomic risks.
FamiCord AG Earnings Call Transcript: Q3 2025
Revenue and EBITDA improved year-over-year, driven by recurring payments and new CDMO contracts. Settled Cryo-Save litigation opens new revenue opportunities, while the placenta business in Germany is set to launch in Q3 next year. M&A activity is limited by capital constraints.
FamiCord AG Transcript: Status Update
Leading European stem cell bank projects strong 2024 growth, with revenue guidance of €85–95 million and EBITDA of €8.7–10.3 million. Market share exceeds 55% in Europe, with expansion focused on new products and geographies. Placenta banking rollout continues, with regulatory delays in Germany but imminent launch in Portugal.
FamiCord AG Earnings Call Transcript: Q2 2025
Stem cell banking penetration in Europe remains low but is recovering, with strong growth in Eastern Europe and new product rollouts like placenta banking. Guidance is realistic, with further EBITDA gains expected from acquisitions and a shift in focus to core operations.